Real-World Comparison of Maribavir to Foscarnet for the Treatment of Cytomegalovirus in Solid Organ and Hematopoietic Stem Cell Transplant Recipients.

Viruses · 2024 · PMC11680184 · PMID 39772196

Europe PMC DOI

hedged sentence

0.1580

closest p · 3.2× alpha

0.1580

boldest claim

The sentences

did not reach statistical significancep = 0.158not close (p > 0.1)

In general, patients demonstrated a trend towards receiving first-line therapy for a longer period of time before switching to FOS, with a median duration of 38 days, although this difference did not reach statistical significance ( p = 0.158).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.